New published evidence reinforces the importance of device choice in asthma control
January 31, 2018 08:45 ET
|
Monaghan Medical Corporation
PLATTSBURGH, N.Y., Jan. 31, 2018 (GLOBE NEWSWIRE) -- A recent article in Pulmonary Pharmacology and Physiology1 provides in vitro evidence that the AEROCHAMBER PLUS® FLOW-VU® valved holding chamber...
Parion Sciences Announces Presentation of Clinical Data with Novel Pulmonary Delivery Device at the 2016 North American Cystic Fibrosis Conference
October 25, 2016 08:14 ET
|
Parion Sciences
DURHAM, N.C., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced that an abstract from its...
Market Data Available on Respiratory Diseases and Infections
June 01, 2016 11:30 ET
|
Insight Pharma Reports
NEEDHAM, MA--(Marketwired - June 01, 2016) - Insight Pharma Reports, a division of Healthtech Publishing, announces a series of leading market research reports focusing on respiratory diseases...
Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European Medicines Agency
January 06, 2016 08:00 ET
|
SteadyMed Therapeutics
VANCOUVER, British Columbia and SAN RAMON, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME), (TSX:COM) and SteadyMed Ltd. (Nasdaq:STDY), today announced that the...
SteadyMed Receives Orphan Drug Designation for Trevyent for the Treatment of Pulmonary Arterial Hypertension
January 05, 2016 07:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
Parion Sciences Announces Upcoming Presentations of Data at the North American Cystic Fibrosis Conference Being Held October 8 through 10, 2015
October 05, 2015 08:12 ET
|
Parion Sciences
Data From Preclinical and Clinical Research on P-1037(VX-371) to be PresentedAdditional Data Presentation Includes a Review of a Novel in Silico Approach Towards Identification of CFTR...
CLEAN-CF Clinical Trial Expanded to Include Pediatric Cystic Fibrosis Population
September 10, 2015 09:35 ET
|
Parion Sciences
DURHAM, N.C., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today that the CLEAN-CF...
Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases
June 04, 2015 16:01 ET
|
Parion Sciences
-ENaC inhibition aims to restore or improve hydration of cell surfaces in the lungs to improve lung function- -Parion to receive $80 million up-front payment with potential for additional development...
Parion Sciences Receives 2015 Life Sciences Award as “Best Late Stage Product Development” Company
May 22, 2015 09:28 ET
|
Parion Sciences
DURHAM, N.C., May 22, 2015 (GLOBE NEWSWIRE) -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today that it was awarded the...
DiamiR Announces Publication and Discusses Merits of Universal Screening Test Based on Organ-Enriched microRNA Signatures
November 03, 2014 08:02 ET
|
DiamiR Biosciences Corp.
MONMOUTH JUNCTION, NJ--(Marketwired - November 03, 2014) - DiamiR Biosciences Corp., a developer of innovative diagnostic tests for neurodegenerative and other diseases, announced today the...